70 results
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
15 May 24
Results of Operations and Financial Condition
4:34pm
of Research and Development, and Chief Medical Officer, added, “We have continued to analyze and publish data from our first-in-human study characterizing
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
5 Apr 24
Other Events
4:33pm
that may lead to enhanced clinical activity,” said Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development
8-K
EX-99.1
jmjosxj
29 Mar 24
Results of Operations and Financial Condition
8:35am
8-K
EX-99.1
n58ln9re7 p7
17 Jan 24
Other Events
8:35am
8-K
EX-99.1
d0ut0r5vxfh6kw2hxxx
9 Jan 24
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
8:11am
8-K
EX-99.1
po3dt yw0y1gyb
9 Nov 23
Results of Operations and Financial Condition
4:41pm
8-K
EX-99.1
ava l5dh3a83o
3 Nov 23
Other Events
5:10pm
8-K
EX-99.1
f3vn leaj202a7id1
27 Sep 23
Other Events
5:41pm
8-K
EX-99.1
kemzgfgx781 sijf2hyd
7 Sep 23
Other Events
8:00am
8-K/A
EX-99.2
swxjnoy9gavzmpvp2v5e
11 Aug 23
Elicio Therapeutics, Inc. Financial Statements
9:13pm
8-K/A
EX-99.3
erfqnat4h5sclbl3
11 Aug 23
Elicio Therapeutics, Inc. Financial Statements
9:13pm
8-K/A
EX-99.1
3q163
11 Aug 23
Elicio Therapeutics, Inc. Financial Statements
9:13pm
8-K
EX-99.1
jchyjya2eo
11 Aug 23
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides
11:42am
8-K
EX-99.1
wxaf71q6a
5 Jun 23
Other Events
8:00am